{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:22:36Z","timestamp":1779294156235,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Province Gastrointestinal, Respiratory, Genitourinary Malignant Tumor Radiotherapy Radiation and Treatment Clinical Medical Research Center","award":["2021Y2014"],"award-info":[{"award-number":["2021Y2014"]}]},{"name":"Fujian Provincial Clinical Medical Research Center for Tumor Precision Radiotherapy","award":["2020Y20101"],"award-info":[{"award-number":["2020Y20101"]}]},{"name":"Fujian Province Science and Technology Innovation Joint Funding Project","award":["2021Y9216"],"award-info":[{"award-number":["2021Y9216"]}]},{"name":"Fujian Province Natural Science Foundation","award":["2021J01438 and 2022J01433"],"award-info":[{"award-number":["2021J01438 and 2022J01433"]}]},{"name":"Fujian Cancer Hospital In-Hospital Funding Program","award":["2021YN10"],"award-info":[{"award-number":["2021YN10"]}]},{"name":"The Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy","award":["2020Y2012"],"award-info":[{"award-number":["2020Y2012"]}]},{"name":"The National Clinical Key Specialty Construction Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93187-y","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:13Z","timestamp":1759237333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses"],"prefix":"10.1038","volume":"15","author":[{"given":"Shiji","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingte","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huipeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qizhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingdong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8975-0489","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1047-2338","authenticated-orcid":false,"given":"Junxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"93187_CR1","doi-asserted-by":"crossref","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. 359(4), 378\u2013390. (2008).","DOI":"10.1056\/NEJMoa0708857"},{"issue":"2","key":"93187_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"11","author":"B Escudier","year":"2007","unstructured":"Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New. Engl. J. Med.. 11(2), 125\u2013134 (2007).","journal-title":"New. Engl. J. Med."},{"key":"93187_CR3","doi-asserted-by":"crossref","unstructured":"Du, W., Shi, X., Fang, Q., Zhang, X. & Liu, S. J. F. E. Feasibility of apatinib in radioiodine-refractory differentiated thyroid carcinoma. 13, 768028. (2022).","DOI":"10.3389\/fendo.2022.768028"},{"issue":"1","key":"93187_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"10","author":"W Tang","year":"2020","unstructured":"Tang, W. et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal. Transduct. Target. Therapy. 10(1), 87 (2020).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"6","key":"93187_CR5","first-page":"868","volume":"28","author":"L An","year":"2021","unstructured":"An, L., Liao, H. & Yuan, K. Efficacy and safety of second-line treatments in patients with advanced hepatocellular carcinoma after sorafenib failure: A meta-analysis. J. Clin. Translational Hepatol. 28(6), 868\u2013877 (2021).","journal-title":"J. Clin. Translational Hepatol."},{"key":"93187_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.semcancer.2019.10.013","volume":"66","author":"LA Booth","year":"2020","unstructured":"Booth, L. A., Roberts, J. L. & Dent, P. The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to Sorafenib and neratinib. Semin. Cancer Biol.. 66, 129\u2013139 (2020).","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"93187_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun, J. W. et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to Sorafenib and lenvatinib. Cancer Commun.. 43(4), 455\u2013479 (2023).","journal-title":"Cancer Commun."},{"issue":"5","key":"93187_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1208\/s12249-022-02214-y","volume":"29","author":"M Tang","year":"2022","unstructured":"Tang, M. et al. Sorafenib-Loaded PLGA-TPGS nanosystems enhance hepatocellular carcinoma therapy through reversing P-Glycoprotein-Mediated multidrug resistance. AAPS PharmSciTech. 29(5), 130 (2022).","journal-title":"AAPS PharmSciTech"},{"key":"93187_CR9","doi-asserted-by":"publisher","first-page":"114402","DOI":"10.1016\/j.biopha.2023.114402","volume":"160","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. XPO1 intensifies Sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma. Biomed. Pharmacotherapy = Biomedecine Pharmacotherapie. 160, 114402 (2023).","journal-title":"Biomed. Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"93187_CR10","doi-asserted-by":"crossref","unstructured":"Billingham, R. E., Brent, L. & Medawar, P. B. J. N. \u2018Actively acquired tolerance\u2019 of foreign cells. 172, 603\u2013606 (1953).","DOI":"10.1038\/172603a0"},{"key":"93187_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-immunol-091319-083608","volume":"26","author":"BD Rudd","year":"2020","unstructured":"Rudd, B. D. Neonatal T cells: A reinterpretation. Annu. Rev. Immunol. 38, 229\u2013247. (2020).","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"93187_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41587-019-0015-4","volume":"37","author":"P Serra","year":"2019","unstructured":"Serra, P. & Santamaria, P. Antigen-specific therapeutic approaches for autoimmunity. Nat. Biotechnol. 37(3), 238\u2013251 (2019).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"93187_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nri.2016.125","volume":"17","author":"P Brodin","year":"2017","unstructured":"Brodin, P. & Davis, M. M. Human immune system variation. Nat. Reviews Immunol.. 17(1), 21\u201329 (2017).","journal-title":"Nat. Reviews Immunol."},{"key":"93187_CR14","doi-asserted-by":"crossref","unstructured":"Oura, K., Morishita, A., Tani, J. & Masaki, T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review. Int. J. Mol. Sci. 28, 22(11). (2021).","DOI":"10.3390\/ijms22115801"},{"issue":"6","key":"93187_CR15","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","volume":"19","author":"A Crinier","year":"2020","unstructured":"Crinier, A., Narni-Mancinelli, E., Ugolini, S. & Vivier, E. SnapShot: natural killer cells. Cell. 19(6), 1280\u20131280e1281 (2020).","journal-title":"Cell."},{"issue":"3","key":"93187_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"1","author":"E Borcoman","year":"2019","unstructured":"Borcoman, E. et al. Novel patterns of response under immunotherapy. Annals Oncology: Official J. Eur. Soc. Med. Oncol. 1(3), 385\u2013396 (2019).","journal-title":"Annals Oncology: Official J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"93187_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41467-022-28421-6","volume":"10","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Machine learning-based integration develops an immune-derived LncRNA signature for improving outcomes in colorectal cancer. Nat. Commun.. 10(1), 816 (2022).","journal-title":"Nat. Commun."},{"issue":"1","key":"93187_CR18","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1038\/s41467-022-32283-3","volume":"6","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat. Commun. 6(1), 4594 (2022).","journal-title":"Nat. Commun."},{"issue":"6","key":"93187_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","volume":"68","author":"R Pinyol","year":"2019","unstructured":"Pinyol, R. et al. Molecular predictors of prevention of recurrence in HCC with Sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 68(6), 1065\u20131075 (2019).","journal-title":"Gut"},{"issue":"1","key":"93187_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"1","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"93187_CR21","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Science: Publication Protein Soc. 28(11), 1947\u20131951 (2019).","journal-title":"Protein Science: Publication Protein Soc."},{"issue":"D1","key":"93187_CR22","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"6","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res.. 6(D1), D587\u2013d592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"93187_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.omtm.2020.11.007","volume":"12","author":"H Ma","year":"2021","unstructured":"Ma, H., Bell, K. N. & Loker, R. N. qPCR and qRT-PCR analysis: regulatory points to consider when conducting biodistribution and vector shedding studies. Mol. Therapy Methods Clin. Dev. 12, 20:152\u2013168 (2021).","journal-title":"Mol. Therapy Methods Clin. Dev."},{"issue":"4","key":"93187_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cac2.12023","volume":"40","author":"WCC Tan","year":"2020","unstructured":"Tan, W. C. C. et al. Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun.. 40(4), 135\u2013153 (2020).","journal-title":"Cancer Commun."},{"issue":"7","key":"93187_CR25","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou, S. L. et al. Tumor-Associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterol. 150(7), 1646\u20131658.e1617 (2016).","journal-title":"Gastroenterol."},{"key":"93187_CR26","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1016\/j.csbj.2023.07.005","volume":"21","author":"R Zheng","year":"2023","unstructured":"Zheng, R. et al. Autophagy and biotransformation affect Sorafenib resistance in hepatocellular carcinoma. Comput. Struct. Biotechnol. J. 21, 3564\u20133574 (2023).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"93187_CR27","doi-asserted-by":"publisher","first-page":"1156383","DOI":"10.3389\/fcell.2023.1156383","volume":"11","author":"K Zhang","year":"2023","unstructured":"Zhang, K., Zhang, Q., Jia, R., Xiang, S. & Xu, L. A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy. Front. Cell. Dev. Biology. 11, 1156383 (2023).","journal-title":"Front. Cell. Dev. Biology"},{"issue":"6491","key":"93187_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.aaz9330","volume":"8","author":"JE Park","year":"2020","unstructured":"Park, J. E., Jardine, L., Gottgens, B., Teichmann, S. A. & Haniffa, M. Prenatal development of human immunity. Science. 8(6491), 600\u2013603 (2020).","journal-title":"Science"},{"key":"93187_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.026","volume":"72","author":"X Zhang","year":"2018","unstructured":"Zhang, X., Wang, W., Li, P., Wang, X. & Ni, K. High TREM2 expression correlates with poor prognosis in gastric cancer. Hum. Pathol. 72, 91\u201399 (2018).","journal-title":"Hum. Pathol."},{"issue":"6","key":"93187_CR30","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3892\/ijo.2016.3740","volume":"49","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K\/Akt pathway. Int. J. Oncol. 49(6), 2498\u20132506 (2016).","journal-title":"Int. J. Oncol."},{"issue":"1","key":"93187_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12160","volume":"259","author":"EM Shevach","year":"2014","unstructured":"Shevach, E. M. & Thornton, A. M. tTregs, pTregs, and iTregs: similarities and differences. Immunol. Rev.. 259(1), 88\u2013102 (2014).","journal-title":"Immunol. Rev."},{"issue":"39","key":"93187_CR32","doi-asserted-by":"publisher","first-page":"e2202157119","DOI":"10.1073\/pnas.2202157119","volume":"27","author":"F Liu","year":"2022","unstructured":"Liu, F. et al. Oncogenic beta-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer. Proc. Natl. Acad. Sci. United States Am. 27(39), e2202157119 (2022).","journal-title":"Proc. Natl. Acad. Sci. United States Am."},{"key":"93187_CR33","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/ncomms3268","volume":"4","author":"J de la Rosa","year":"2013","unstructured":"de la Rosa, J. et al. Prelamin A causes Progeria through cell-extrinsic mechanisms and prevents cancer invasion. Nat. Commun. 4, 2268 (2013).","journal-title":"Nat. Commun."},{"issue":"11","key":"93187_CR34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"14","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell.. 14(11), 1407\u20131422.e1407 (2022).","journal-title":"Cancer Cell."},{"issue":"5","key":"93187_CR35","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.apsb.2019.05.001","volume":"9","author":"CP Chen","year":"2019","unstructured":"Chen, C. P., Chen, K., Feng, Z., Wen, X. & Sun, H. Synergistic antitumor activity of Artesunate and HDAC inhibitors through elevating Heme synthesis via synergistic upregulation of ALAS1 expression. Acta Pharm. Sinica B 9(5), 937\u2013951 (2019).","journal-title":"Acta Pharm. Sinica B"},{"key":"93187_CR36","doi-asserted-by":"crossref","unstructured":"Koyas, A. et al. Interleukin-7 protects CD8(+) T cells from adenosine-mediated immunosuppression. Sci. Signal. 14, 674 (2021).","DOI":"10.1126\/scisignal.abb1269"},{"issue":"10","key":"93187_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/imcb.12594","volume":"100","author":"S Jalali","year":"2022","unstructured":"Jalali, S. et al. A high-dimensional cytometry atlas of peripheral blood over the human life span. Immunol. Cell. Biol.. 100(10), 805\u2013821 (2022).","journal-title":"Immunol. Cell. Biol."},{"issue":"4","key":"93187_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol.. 4(4), 330\u2013336 (2003).","journal-title":"Nat. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93187-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93187-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93187-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:18Z","timestamp":1759237338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93187-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93187"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93187-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have approved the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33731"}}